UBS Group
ALT icon

UBS Group’s Altimmune ALT Stock Holding History

UBS Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-275,500
Closed -$995K – 10437
2025
Q4 		$995K Sell
275,500
-10,400
-4% -$45.3K ﹤0.01% 5581
2025
Q3 		$1.08M Buy
+285,900
New +$1.1M ﹤0.01% 5512
2022
Q4 		– Sell
-6,600
Closed -$84K – 10689
2022
Q3 		$84K Buy
+6,600
New +$97.4K ﹤0.01% 5855
2015
Q1 		– Sell
-5
Closed -$3K – 8746
2014
Q4 		$3K Buy
+5
New +$2.57K ﹤0.01% 9212

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS Group's ALT Position: Q1 2026 in Review

UBS Group increased its Altimmune (ALT) stake by 41% in Q1 2026, buying an estimated $1.12M and bringing the position to 904,768 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4664.

UBS Group first reported a position in ALT in Q4 2014 and has held it in 42 quarters since. The position peaked at $15.8M in Q4 2020. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • UBS Group held 904,768 shares of Altimmune worth $2.79M as of Q1 2026.
  • UBS Group bought 262,720 Altimmune shares in Q1 2026, an estimated $1.12M.
  • Altimmune made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4664 holding.
  • UBS Group first reported a position in Altimmune in Q4 2014 and has held it in 42 quarters since.
  • UBS Group's Altimmune position peaked at $15.8M in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.